Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 9Unknown 5Withdrawn 4Terminated 2Suspended 2Recruiting 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Breast Neoplasms 430Neoplasms 284Carcinoma, Non-Small-Cell Lung 266Colorectal Neoplasms 228Lung Neoplasms 173Prostatic Neoplasms 171Carcinoma, Hepatocellular 156Stomach Neoplasms 129Leukemia, Myeloid, Acute 118Pancreatic Neoplasms 115Multiple Myeloma 105Recurrence 96Uterine Cervical Neoplasms 91Squamous Cell Carcinoma of Head and Neck 88Neoplasm Metastasis 87Rectal Neoplasms 85Ovarian Neoplasms 77Triple Negative Breast Neoplasms 75Small Cell Lung Carcinoma 72Head and Neck Neoplasms 68Brain Neoplasms 68Esophageal Neoplasms 64Glioblastoma 63Colonic Neoplasms 60Endometrial Neoplasms 58Melanoma 54Hematologic Neoplasms 53Motor Activity 50Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Nasopharyngeal Carcinoma 46

Interventions

resiniferatoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Interventional × Pain, Intractable × Clear all
NCT02522611 2026-04-13

Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain

National Institutes of Health Clinical Center (CC)

Phase 1/2 Not yet recruiting
30 enrolled

Cancer Pain, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡